Financial Performance - The company's revenue for Q1 2025 was CNY 1,299,820,581.67, representing a 1.51% increase compared to CNY 1,280,469,171.09 in the same period last year[5] - Net profit attributable to shareholders decreased by 83.82% to CNY 3,144,357.36 from CNY 19,436,945.89 year-on-year[5] - The diluted earnings per share decreased by 77.78% to CNY 0.02 from CNY 0.09 in the same period last year[5] - Net profit for the current period was ¥10,626,439.28, down from ¥22,059,938.81 in the previous period, indicating a decline of approximately 51.8%[22] - The total comprehensive income attributable to the parent company was ¥3,144,357.36, down from ¥19,436,945.89, a decrease of approximately 83.8%[23] Cash Flow - The net cash flow from operating activities was negative at CNY -201,387,255.36, a decline of 14.76% compared to CNY -175,488,409.39 in the previous year[11] - The net cash flow from investing activities was -$54,606,958.46, indicating a significant outflow compared to the previous period's -$425,988,313.13[25] - The net cash flow from financing activities was $156,977,132.25, a decrease from $338,974,376.99 in the previous period[25] - The ending cash and cash equivalents balance was $421,992,791.70, down from $354,815,404.93, indicating a decline in liquidity[25] - The net increase in cash and cash equivalents was -$99,017,081.57, compared to -$262,502,345.53 in the prior period, showing an improvement in cash management[25] Assets and Liabilities - Total assets increased by 4.29% to CNY 6,443,038,507.14 from CNY 6,178,190,385.57 at the end of the previous year[5] - Current assets amounted to CNY 3,979,298,487.91, up from CNY 3,711,405,478.30 at the start of the period, reflecting a growth of approximately 7.2%[18] - Total liabilities rose to CNY 4,583,840,753.45 from CNY 4,329,490,087.12, indicating an increase of about 5.9%[19] - The company’s long-term borrowings increased significantly to CNY 1,199,788,511.39 from CNY 885,846,727.60, a rise of approximately 35.4%[19] Research and Development - Research and development expenses rose by 50.98% to CNY 3,113,060.00, driven by increased drug development costs in the industrial sector[10] - Research and development expenses increased to ¥3,113,060.00 from ¥2,061,921.04, marking a rise of approximately 50.9%[21] Other Income and Expenses - The company reported a significant increase of 136.30% in other income, totaling CNY 10,241,664.14, due to tax relief from government subsidies for retail chain enterprises[10] - Other income rose to ¥10,241,664.14 from ¥4,334,261.80, reflecting an increase of about 136.5%[21] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,780, with the largest shareholder holding 34.15% of the shares[12] - The minority shareholders' profit increased to ¥7,482,081.92 from ¥2,622,992.92, indicating a growth of approximately 184.5%[23] Company Developments - The company received a drug registration certificate for Oseltamivir Phosphate Granules from the National Medical Products Administration[16] - The company completed the investment project for the "Dajia Weikang Pharmaceutical Industrial Base" and decided to conclude it[16] - The company is actively updating its fundraising documents in response to inquiries from the Shenzhen Stock Exchange[16] Accounting and Audit - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[26] - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[27]
达嘉维康(301126) - 2025 Q1 - 季度财报